반응식
[Cl:1][C:2]1[CH:3]=[C:4]([NH:9][C:10]2[C:11]3[CH2:18][C:17](=[O:19])[NH:16][C:12]=3[N:13]=[CH:14][N:15]=2)[CH:5]=[CH:6][C:7]=1[F:8].[CH:20]([C:22]1[NH:26][C:25]([CH3:27])=[C:24]([CH2:28][CH2:29][C:30]([OH:32])=[O:31])[C:23]=1[CH3:33])=O>N1CCCCC1.C(O)C>[Cl:1][C:2]1[CH:3]=[C:4]([NH:9][C:10]2[C:11]3[C:18](=[CH:20][C:22]4[NH:26][C:25]([CH3:27])=[C:24]([CH2:28][CH2:29][C:30]([OH:32])=[O:31])[C:23]=4[CH3:33])[C:17](=[O:19])[NH:16][C:12]=3[N:13]=[CH:14][N:15]=2)[CH:5]=[CH:6][C:7]=1[F:8]참가 물질
5
반응물 2
생성물 1
시약·촉매·용매 2
실험 절차
A mixture of 4-(3-chloro-4-fluoro-phenylamino)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one (6.3 mg, 0.0226 mmol), 3-(5-formyl-2,4-dimethyl-1H-pyrrol-3-yl)-propionic acid (4.9 mg, 0.0249 mmol) and piperidine (4 drops) in ethanol (1 mL) was stirred at room temperature for 24 hours. The reaction was concentrated and purified (reversed phase HPLC) to give 5.2 mg (51%) of the title compound. MS 456.4 [M++1].
후처리
- concentrationThe reaction was concentrated
- custompurified (reversed phase HPLC)
출처 및 근거
- ORD 기록
- ord-e74c8518e8f84622b0e8390bab0de70b
- 출처 데이터셋
- uspto-grants-2003_08
- 특허 번호
- US06610688B2
연결된 노트
불러오는 중…